Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia

J Pediatr Hematol Oncol. 2020 May;42(4):e258-e261. doi: 10.1097/MPH.0000000000001572.

Abstract

T-cell therapy-related acute lymphoblastic leukemia (T-t-ALL) is a rare condition associated with previous cytotoxic therapy for another disease. Here we report T-t-ALL with inv(11)(q21q23), which involves KMT2A and MAML2, a transcriptional coactivator of NOTCH proteins, that occurred after chemotherapy for Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. This case describes the youngest patient with T-t-ALL harboring inv(11)(q21q23) and is the first independent report following an initial series also occurring in children. Our results lend further support to the observation that the KMT2A-MAML2 fusion gene resulting from inv(11)(q21q23) is likely a recurrent cytogenetic abnormality in T-t-ALL and appears to be associated with pediatric cases.

Publication types

  • Case Reports

MeSH terms

  • Child, Preschool
  • Chromosome Inversion*
  • Chromosomes, Human, Pair 11*
  • Histone-Lysine N-Methyltransferase / genetics*
  • Humans
  • Male
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Neoplasms, Second Primary / genetics*
  • Neoplasms, Second Primary / pathology
  • Oncogene Proteins, Fusion / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Trans-Activators / genetics*

Substances

  • KMT2A protein, human
  • MAML2 protein, human
  • Oncogene Proteins, Fusion
  • Trans-Activators
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase